Fig. 3From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemiaPFS according to EOT CD4, and according to EOT MRD levels. (A) PFS curves according to EOT CD4 status in patients with undetectable (< 10−4) EOT MRD (p = 0.6998). (B) PFS curves according to EOT CD4 status in patients with detectable (≥10− 4) EOT MRD (p = 0.0004)Back to article page